Literature DB >> 7550979

Sensitive gas-liquid chromatographic method for the assay of the neuroleptic drug cis(Z)-flupentixol in human serum or plasma.

S Ulrich1.   

Abstract

A gas-liquid chromatographic (GLC) assay suitable for the analysis of the cis(Z)-stereoisomer of the antipsychotic drug flupentixol in human serum or plasma was developed. The minimal quantifiable concentration was 0.5 ng/ml and the day-to-day coefficient of variation was 11.2% at 1 ng/ml and 8.7% at 10 ng/ml. Following addition of perphenazine as the internal standard (I.S.) and aqueous NaOH, samples (2 ml) are extracted with n-hexane-isoamyl alcohol (98.5:1.5, v/v) (solvent), back-extracted to 0.1 M HCl and after one washing-step and addition of aqueous NaOH again extracted into 100 microliters solvent. After evaporation to dryness, the extract is reconstituted in 20 microliters solvent and evaporated to approximative 10 microliters. A 4-microliter aliquot is injected cool on-column onto the GLC system. A gas chromatograph HP 5890 with on-column injection port, nitrogen-phosphorus detector (NPD), a HP-1 25 m x 0.32 mm I.D., 0.52 micron capillary and hydrogen (3 ml/min, automated pressure control) as the carrier gas was applied. The negative influence of light on the assay was measured and discussed. The suitability of this method for clinical pharmacokinetic studies and therapeutic drug monitoring (TDM) was determined by the analysis of serum samples of 12 schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550979     DOI: 10.1016/0378-4347(95)00057-p

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  2 in total

1.  Flupentixol: relevance of stereoselective therapeutic drug monitoring.

Authors:  Pierre Baumann; Hartmut Kirchherr; Patricia Berney; Christoph Hiemke
Journal:  Psychopharmacology (Berl)       Date:  2012-04-04       Impact factor: 4.530

Review 2.  The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.

Authors:  S Ulrich; C Wurthmann; M Brosz; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.